- Home
- BIIB vs KEY Comparison
BIIB vs KEY Comparison
Compare BIIB & KEY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- KEY
- Stock Information
- Founded
- BIIB 1978
- KEY 1825
- Country
- BIIB United States
- KEY United States
- Employees
- BIIB N/A
- KEY N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- KEY Major Banks
- Sector
- BIIB Health Care
- KEY Finance
- Exchange
- BIIB Nasdaq
- KEY Nasdaq
- Market Cap
- BIIB 18.7B
- KEY 20.8B
- IPO Year
- BIIB 1991
- KEY N/A
- Fundamental
- Price
- BIIB $149.17
- KEY $18.27
- Analyst Decision
- BIIB Buy
- KEY Buy
- Analyst Count
- BIIB 26
- KEY 16
- Target Price
- BIIB $182.82
- KEY $20.41
- AVG Volume (30 Days)
- BIIB 1.8M
- KEY 27.3M
- Earning Date
- BIIB 10-30-2025
- KEY 10-16-2025
- Dividend Yield
- BIIB N/A
- KEY 4.51%
- EPS Growth
- BIIB 31.67
- KEY N/A
- EPS
- BIIB 10.45
- KEY 0.03
- Revenue
- BIIB $9,997,000,000.00
- KEY $4,743,000,000.00
- Revenue This Year
- BIIB $2.00
- KEY $76.60
- Revenue Next Year
- BIIB N/A
- KEY $6.10
- P/E Ratio
- BIIB $14.31
- KEY $569.32
- Revenue Growth
- BIIB 3.36
- KEY N/A
- 52 Week Low
- BIIB $110.04
- KEY $12.73
- 52 Week High
- BIIB $194.13
- KEY $20.04
- Technical
- Relative Strength Index (RSI)
- BIIB 56.57
- KEY 40.76
- Support Level
- BIIB $135.39
- KEY $18.35
- Resistance Level
- BIIB $160.20
- KEY $19.04
- Average True Range (ATR)
- BIIB 4.43
- KEY 0.40
- MACD
- BIIB 0.56
- KEY -0.08
- Stochastic Oscillator
- BIIB 54.23
- KEY 22.69
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About KEY KeyCorp
With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.